U.S – In a bid to uphold the highest standards of food safety, the U.S. Food and Drug Administration (FDA) has issued warning letters to three prominent infant formula manufacturers: ByHeart, Reckitt/Mead Johnson Nutrition, and Perrigo Wisconsin.
These stern warnings come as a response to infractions of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the FDA’s Infant Formula regulations.
While the FDA acknowledges the corrective action responses submitted by these companies, it has identified areas that require further attention.
These warning letters are a result of findings from facility inspections that revealed deviations from regulatory requirements.
Importantly, they are not associated with current recalls, and the FDA assures that there will be no disruption in the availability of infant formula on the market.
These companies have, in the past, conducted recalls to remove products potentially contaminated with Cronobacter sakazakii, a pathogen that played a pivotal role in the 2022 U.S. infant formula crisis.
Donald Prater, acting Director of the FDA’s Center for Food Safety and Applied Nutrition, emphasizes the shared responsibility of infant formula manufacturers to ensure product safety.
“The FDA is committed to identifying and acting on issues early to prevent any firms from reaching the level of concern that prompted last year’s large-scale recall and contributed to the infant formula shortage,” he said.
Crucially, the FDA does not advise parents and caregivers to discard or avoid purchasing specific infant formulas.
The agency affirms that there is no information regarding the distribution of contaminated products. It believes that the recalls effectively removed potentially compromised batches from the market.
Enhancing regulatory oversight
Warning letters are an integral component of the FDA’s regulatory process. They serve to underscore the importance of implementing and sustaining appropriate corrective actions when pathogen issues arise.
The FDA mandates thorough root cause investigations, rigorous cleaning and sanitation measures, and a comprehensive evaluation of hygiene practices.
The companies have a 15-working-day window to detail the corrective actions they are taking. The FDA will then assess the adequacy of these actions through a review of the responses and on-site facility inspections to verify their implementation.
These warning letters are part of the FDA’s broader strategy to prevent future contaminations and shortages in the infant formula market.
The agency has been working closely with Congress to bolster its regulatory capabilities and increase funding for infant formula industry oversight.
Additionally, the FDA has collaborated with the U.S. Centers for Disease Control and Prevention (CDC) to address Cronobacter infections among infants under one year old. This condition has been added to the Nationally Notifiable Conditions List, providing comprehensive disease reporting in the U.S.
The FDA underscores the importance of adhering to manufacturer instructions for preparing powdered infant formula and advises heating water to a minimum of 158°F/70°C before mixing it with powdered formula as an added safety measure against Cronobacter.
In the wake of the 2022 infant formula shortage, vigilance and proactive measures are paramount to ensure the safety and well-being of infants relying on these crucial products.